Agaricus blazei (Himematsutake) does not alter the development of rat diethylnitrosamine-initiated hepatic preneoplastic foci

Cancer Science

Volumn 94, Issue 2, 2003, Pages 188-192

  Barbisan, Luís Fernando ^a   Spinardi Barbisan, Ana Lúcia Tozzi ^a   Trindade Moreira, Eduardo Luís ^b   Favero Salvadori, Daisy Maria ^a   Ribeiro, Lúcia Regina ^a,c   Ferreira da Eira, Augusto ^d   Viana de Camargo, João Lauro ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^d Faculdade de Ciencias Agronomicas   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AGARICUS EXTRACT; BROXURIDINE; CYCLOPHOSPHAMIDE; DIETHYLNITROSAMINE; EOSIN; GLUTATHIONE TRANSFERASE; HEMATOXYLIN; PLANT EXTRACT; UNCLASSIFIED DRUG;

AGARICUS BLAZEI; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SYNTHESIS; IMMUNOHISTOCHEMISTRY; LIVER CANCER; LIVER CARCINOGENESIS; LIVER PARENCHYMA; LIVER PROTECTION; LIVER RESECTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

AGARICUS; ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; BRAZIL; BROMODEOXYURIDINE; CELL DIVISION; DIETHYLNITROSAMINE; DNA REPLICATION; DRUG SCREENING ASSAYS, ANTITUMOR; GLUTATHIONE TRANSFERASE; HEPATOCYTES; LIVER DISEASES; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MEDICINE, TRADITIONAL; NEOPLASM PROTEINS; ORGAN SIZE; PHYTOTHERAPY; PLANT EXTRACTS; PRECANCEROUS CONDITIONS; RATS; RATS, WISTAR; TUMOR MARKERS, BIOLOGICAL; WATER;

EID: 0038636337     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2003.tb01417.x     Document Type: Article

References (28)

1. Chang R. Functional properties of edible mushrooms. Nutr Rev 1996; 54: S91-3.
2. Fujimiya Y, Suzuki Y, Takakura R, Ebina T. Tumor-specific cytocidal and immunopotentiating effects of relatively low molecular weight products derived from the basidiomycetes, Agaricus blazei Murrill. Anticancer Res 1999; 19: 113-8.
3. Takaku T, Kimura Y, Okuda H. Isolation of an antitumor compound from Agaricus blazei Murrill and its mechanism of action. J Nutr 2001; 131: 1409-13.
4. Delmanto RD, de Lima PLA, Sugui MM, da Eira AF, Salvadori DMF, Speit G, Ribeiro LR. Antimutagenic effects of Agaricus blazei Murrill mushroom on the genotoxicity induced by cyclophosphamide. Mutat Res 2001; 496: 15-21.
5. Menoli RCR, Mantovani MS, Ribeiro RL, Speit G, Jordõ BQ. Antimutagenic effects of the mushroom Agaricus blazei Murrill extracts on V79 cells. Mutat Res 2001; 496: 5-13.
6. Barbisan LF, Miyamoto M, Scolastici C, Salvadori DMF, Ribeiro LR, da Eira AF, de Camargo JLV. Influence of aqueous extract of Agaricus blazei mushroom on rat liver toxicity induced by different doses of diethylnitrosamine. J Ethnopharmacol 2002; 83: 25-32.
7. Kawagishi H, Inagaki R, Kanao T, Mizuno T, Shimura K, Ito H, Hagiwara T, Nakamura T. Fractionation and antitumor activity of the water-insoluble residue of Agaricus blazei fruiting bodies. Carbohydr Res 1989; 186: 267-73.
8. Itoh H, Ito H, Amano H, Noda H. Inhibitory action of a (1→6)-β-D-glucan-protein complex (FIII-2-b) isolated from Agaricus blazei Murrill ("Himematsutake") on Meth A fibrosarcoma-bearing mice and its antitumor mechanism. Jpn J Pharmacol 1994; 66: 265-71.
9. Ito H, Shimura K, Itoh H, Kawade M. Antitumor effects of a new polysaccharide-protein complex (ATOM) prepared from Agaricus blazei (Iwade Strain 101) "Himematsutake" and its mechanisms in tumor-bearing mice. Anticancer Res 1997; 17: 277-84.
10. Dragan YP, Rizvi T, Xu Y-H, Hully JR, Bawa N, Campbell HA, Maronpot RR, Pitot HC. An initiation-promotion assay in rat liver as a potential complement to the 2-year carcinogenesis bioassay. Fundam Appl Toxicol 1991; 16: 525-47.
11. Ito N, Tsuda H, Tatematsu M, Inoue T, Tagawa Y, Aoki T, Uwagawa S, Kagawa M, Ogiso T, Masui T, Imaida K, Asamoto M. Enhancing effect of various hepatocarcinogens on induction of preneoplastic glutathione S-transferase placental form positive foci in rats; an approach for a new medium-term bioassay system. Carcinogenesis 1988; 9: 387-94.
12. Ito N, Hasegawa R, Imaida K, Hirose M, Shirai T. Medium-term liver and multi-organ carcinogenesis bioassay for carcinogens and chemopreventive agents. Exp Toxicol Pathol 1996; 48: 113-9.
13. Moore M, Tsuda H, Tamano S, Hagiwara A, Imaida K, Shirai T, Ito N. Marriage of a medium-term liver model to surrogate markers-a practical approach for risks and benefit assessment. Toxicol Pathol 1999; 27: 237-42.
14. Hsu SM, Raine L, Fanger N. Use of avidin-biotin-peroxidase complex (ABC) and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 557-80.
15. Goodman DG, Maronpot RR, Newberne PM, Popp JA, Squire RA. Proliferative and selected other lesions in the liver of rats. In: Guides for toxicologic pathology. Washington: STP/ARP/AFIP; 1994. p. 1-22.
16. Dragan YP, Hully J, Mass M, Pitot HC. Incorporation of bromodeoxyuridine in glutathione S-transferase-positive hepatocytes during rat multistage hepatocarcinogenesis. Carcinogenesis 1994; 15: 1939-47.
17. Goldsworthy TL, Fransson-Steen R, Maronpot RR. Importance of and approaches to quantification of hepatocyte apoptosis. Toxicol Pathol 1996; 24: 24-35.
18. Levin S, Bucci TJ, Cohen SM, Fix AS, Hardisty JF, LeGrand EK, Maronpot RR, Trump BF. The nomenclature of cell death: recommendations of an ad hoc committee of the Society of Toxicology pathologists. Toxicol Pathol 1999; 27: 484-90.
19. Snedecor GW, Cochran WG. Statistical methods. 7th ed. Ames: Iowa State University Press; 1980. p. 1-507.
20. Wasser SP, Weis AL. Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit Rev Immunol 1999; 19: 65-96.
21. Ooi VEC, Liu F. A review of pharmacological activities of mushroom polysaccharides. Int J Med Mushrooms 1999; 1: 195-206.
22. McPartland JM, Vilgalys RJ, Cubeta MA. Mushroom poisoning. Am Fam Physician 1997; 55: 1797-809.
23. Larry D, Pageaux GP. Hepatotoxicity of herbal remedies and mushrooms. Semin Liver Dis 1995; 15: 183-8.
24. Toth B. Mushroom toxins and cancer. Int J Oncol 1995; 6: 137-45.
25. Schulte-Hermann R, Timmermann-Trosiener I, Barthel G, Bursch W. DNA synthesis, apoptosis, and phenotypic expression as determinants of growth of altered foci in rat liver during phenobarbital promotion. Cancer Res 1990; 50: 5127-35.
26. Stinchocombe S, Buchmann A, Bock KM, Schwarz M. Inhibition of apoptosis during 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated tumor promotion in rat liver. Carcinogenesis 1995; 16: 1271-5.
27. Schulte-Hermann R, Bursch W, Grasl-Kraupp B, Müllauer L, Ruttkay-Nedecky B. Apoptosis and multistage carcinogenesis in rat liver. Mutat Res 1995; 333: 81-7.
28. Grasi-Kraupp B, Ruttkay-Nedecky B, Müllauer L, Taper H, Huber W, Bursch W, Schulte-Hermann, R: Inherent increase of apoptosis in liver tumors: implications for carcinogenesis and tumor regression. Hepatology 1997; 25: 906-12.